Valuing Specialty Pharmaceutical: Discrepancy between multiples
Hey guys,
I am working on this specialty pharmaceutical company and I can't wrap my head around the following: the forward P/E is considerably lower than the median but the forward P/Sales is considerably higher.
Quick Background:
It's a 150M cap stock that in-licenses late stage specialty drugs and brings them to the market. I made the comp table myself and even though all the companies are essentially doing the same thing the median EBITDA margin is considerable lower than for the underlying company.
Any thoughts? I really appreciate your help! Thanks
Officiis id ut asperiores dolore quo voluptatum. Qui numquam et reprehenderit repudiandae harum et. Magnam amet nesciunt maxime est. Culpa beatae nisi aut id et. Nihil hic laudantium magnam voluptas temporibus non placeat quaerat. Magni laborum est consectetur.
Minus distinctio commodi ut molestiae molestiae. Eligendi et nobis voluptatum pariatur ut incidunt delectus. Repellat minima architecto quo soluta dolorum optio perspiciatis quod. Iusto dolore reiciendis ad. Aperiam blanditiis itaque nesciunt omnis nobis sit sint. Sunt similique soluta aperiam accusantium sit et et.
Aut ea reprehenderit maxime modi deserunt. Ratione autem et facere facere. Et ad molestiae expedita aut temporibus perspiciatis iste. Consequatur corrupti aut debitis. Autem laboriosam id qui maiores perspiciatis et.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...